Purpose: Multiple immune functions such as activation of T cells and monocytes or cytolysis of tumor cells are mediated via the adhesion receptor/ligand pairs CD2/LFA-3 and LFA-1I/CAM-1. Because soluble forms of LFA-3 (sLFA-3) and ICAM-1 (sICAM-1) can interfere with these functions, we asked whether increased levels of sLFA-3 and/or sICAM-l can be found in malignant or inflammatory effusions compared with transudates. Methods: sLFA-3 and sICAM-1 levels were measured by enzyme-linked immunoassays in pleural effusions from 70 patients (6 transudates, 10 inflammatory, 47 malignant, and 7 other effusions).
B-cell differentiation, 4, 21, 22 and T-cell activation 5, 6, 23, 24 Although initially described as membrane-anchored molecules, ICAM-1 and LFA-3 also exist as soluble molecules (sICAM-1 and sLFA-3). 15 Purpose: Multiple immune functions such as activation of T cells and monocytes or cytolysis of tumor cells are mediated via the adhesion receptor/ligand pairs CD2/LFA-3 and LFA-1I/CAM-1. Because soluble forms of LFA-3 (sLFA-3) and ICAM-1 (sICAM-1) can interfere with these functions, we asked whether increased levels of sLFA-3 and/or sICAM-l can be found in malignant or inflammatory effusions compared with transudates. Methods: sLFA-3 and sICAM-1 levels were measured by enzyme-linked immunoassays in pleural effusions from 70 patients (6 transudates, 10 inflammatory, 47 malignant, and 7 other effusions).
Twenty pleural fluid samples were tested in parallel for the complete sLFA-3 molecule or sLFA-3-domain 1 only. Results: Increased levels of sICAM-1 were found in all types of exudates compared with transudates. Highest levels of sICAM-1 were measured in malignant exudates, particularly in effusions caused by mesotheliomas, non-small lung cancers, and gynecologic malignancies. This was also true for sLFA-3. However, sLFA-3 levels were not increased in inflammatory effusions. sLFA-3 levels correlated significantly with protein, cholesterol, lactate dehydrogenase, and sICAM-1 levels. Comparison of sLFA-3-domain 1 and the complete sLFA-3 molecule revealed identical sLFA-3 levels, suggesting the absence of nonfunctional split products. Conclusions: Elevated levels of the complete sLFA-3 molecule were found in malignant pleural effusions, while sICAM-l level was elevated in both inflammatory and malignant effusions. Secretion of sICAM-1 and sLFA-3 by tumor cells might block T-cell-mediated immune functions such as tu- The assay wxas performed essentially as previously described.'5 Briefly, a 96-well flat-bottom microtiter plate was coated xvith 100 pL of mAb TS2/9 (5 pg/mL) overnight in the cold room. After 2 washes xwith phosphate-buffered saline solution (PBS)/0.1% polysorbate (Twxeen 20; Sigma, Munich, Germany), the plates were blocked Nvith PBS/1% bovine serum albumin (BSA) for 1 h followed by washing twice and antigen incubation using nondiluted serum or dilutions of recombinant LFA-3. After 2 h and 5 times xvashing, plates were incubated with 5 pg/mL of mAb AICD58.1 or an irrelevant isotype-matched mAb directed at HLA class I (W6/32, IgG2a, ATCC) for l h. Finally, after washing 3 times the wells were incubated for 1 h with goat anti-mouse IgG2a coupled to alkaline phosphatase (Dunn; Asbach, Germany), wvashed 3 times, and developed at room temperature using pnitrophenyl-phosphate (Sigma; Munich, Germany). The reaction was stopped after 15 min by the addition of 3 M NaOH, and the absorbance xvas determined at 405 nm using an ELISA reader (Titertek). Nonspecific binding was defined as an absorbance of more than twvice the background absorbance using the control mAb.
These samples were excluded from the study (nine samples).
Intra-assay variation vas betveen 3% and 6.4%, interassay variation was between 2.8% and 7.6%.
Clinical Investigations sLFA-3 Assay (Domain 1 and 2) The complete LFA-3 molecule was measured by a sandwich-type enzyme-linked immunoassay as above using the anti-LFA-3 mAb AICD58. 16 (Fig  1, top) . Since malignant effusions showed highest levels and constituted the largest group of samples, subgroup analysis was performed dividing samples into effusions due to primary lung tumors (small cell and non-small cell lung cancer), primary tumors of the pleura (mesotheliomas), and effusions due to metastasis consisting of nongynecologic tumors, breast cancer, and gynecologic tumors (ovarian and uterine carcino- (Fig 3) .
Correlation of sLFA-3 and sICAM-1 With Diagnostic Parameters of Pleural Effusions
A small but significant correlation was found between sICAM-1 and sLFA-3 levels in 62 pleural effusions investigated (r=0.43, p=0.001). In addition, sLFA-3 correlated significantly with protein (r=0.48, p<0.0001), cholesterol (r=0.36, p=0.004), and LDH levels (r=0.28, p=0.03). In contrast, no correlation was found between sICAM-1 and these parameters or with soluble adhesion molecules and age (Table 2 ).
DISCUSSION
We found increased concentrations of the soluble adhesion molecules sICAM-1 and sLFA-3 in exudative pleural effusions, particularly malignant effusions caused by non-small cell lung cancers, mesotheliomas, and gynecologic tumors. While sICAM-1 level was increased in all exudates, including inflammatory pleural effusions, sLFA-3 levels in inflammatory effusions were only slightly increased compared with transudates. Lung In certain compartments such as the pleural space, they could either reflect capillary leakage or result from local production. Previous in vitro studies suggest that release of soluble LFA-3 and ICAM-1 is not related to cell death. '5 In our patient population, no correlation was found between sICAM-1 and LDH, a laboratory marker associated with cytolysis. The correlation of sLFA-3 with LDH was poor (r=0.28). Therefore, cytolysis does not appear to be responsible for increased sLFA-3 and sICAM-1 levels. Protein and cholesterol levels reflect capillary leakage in pleural effusions. A slight but significant correlation was found between sLFA-3 and cholesterol as well as sLFA-3 and protein levels. Neither protein nor cholesterol levels correlated with sICAM-1. Thus, sLFA-3 but not sICAM release seems to be due in part to capillary leakage. However, the correlation of sICAM-1 with sLFA-3 levels suggests a similar release mode for both molecules. To this end, sICAM-1 seems to be released within the pleural space and sLFA-3 seems to be released by both capillary leakage and local production.
In the past, release of sLFA-3 and sICAM-1 has been shown to be somewhat independent of its membrane expression because some tumor cell lines show strong membrane expression but no release of sLFA-3.
However, almost all tumor cell lines that secrete sICAM-1 and sLFA-3 in the first place enhance their membrane expression and their sICAM-1/sLFA-3 release on stimulation.'5'4' To this end, production of soluble adhesion molecules often indirectly reflects membrane expression. One might, therefore, envisage a situation in which inflammatory processes within the pleura due to either malignancy or lung inflammation may lead to cytokine secretion, increased expression of membrane-bound ICAM-1 and LFA-3, as well as increased release of soluble ICAM-1 and LFA-3. Just looking at inflammation, this might be a regulatory mechanism to limit adhesion processes by interference with cell-cell interactions. As a side effect of the nonspecific inflammatory response, increased levels of soluble adhesion molecules might interfere with effective cytotoxic reactions impairing the host ability to control tumor cells. Among malignant effusions, soluble adhesion molecules, alternatively, may be released by tumor cells themselves, particularly after local cytokine stimulation. Again, by competion with membrane-bound LFA-3 and/or ICAM-1, these soluble molecules may interfere with cell-cell adhesion, which is required for effective tumor defense by cytotoxic T lymphocytes or NK cells. This might be a mechanism oftumor cells to escape tumor cell surveillance by cytotoxic lymphocytes. 29, 30 Indeed, we and others have shown in vitro that soluble forms of LFA-3 and/or ICAM-1 can interfere with cyototoxic reactions.5'629 To be functionally active, sLFA-3 must comprise the complete molecule consisting of domains 1 and 2. Therefore, split products such as LFA-3 domain 1 bind only weakly, whereas the complete LFA-3 molecule (domains 1 and 2) binds strongly to CD2.5 sLFA-3 in pleural effusions exists in a potentially active form comprising the complete extracellular part of LFA-3 consisting ofboth domains. This is particularly relevant because increased sLFA-3 concentrations were measured by an ELISA against domain 1 of LFA-3, which also detects its nonfunctional split products. Furthermore, adequate concentrations have to be reached before sLFA-3 and/or sICAM-1 can block cellular interactions. These minimum concentrations have been reported to be 100 to 200 ng/mL for sLFA-3 and about 1,000 ng/mL for sICAM-1.1529 Such sICAM-1 levels can be reached by only some malignant pleural effusions, while sLFA-3 concentrations in this range are unlikely. However, if only some cells, eg, tumor cells, produce the majority of these molecules, adequate local concentrations could be reached. The concentrations for triggering of the ligand binding cells are thought to be much higher than for blocking cellular interactions.42 Even locally such concentrations are highly unlikely to be reached in vivo.
In conclusion, increased levels of a potentially active form of sLFA-3 were found in malignant pleural effusions, while sICAM-1 was found to be elevated in both inflammatory and malignant effusions. Therefore, sICAM-1 and sLFA-3 may be an epiphenomenon of the generalized inflammation in both malignant and inflammatory pleural effusions. By interference with cell-cell interactions, they may either limit the extent of inflammation or, alternatively, inhibit effective cytolysis of tumor cells by cytotoxic T lymphocyte and NK cells.
